Lepu Biopharma Co., Ltd.
↗Shanghai, China
Lepu Biopharma is an innovation-driven biopharmaceutical company based in China, focused on the discovery, development, and commercialization of oncology therapeutics. The company specializes in targeted therapies and immunotherapies, with a particular emphasis on antibody-drug conjugates (ADCs) through its advanced proprietary technology platform.
Founded in 2018, the company has established an integrated, end-to-end platform encompassing drug discovery, clinical development, CMC, and GMP-compliant manufacturing. Lepu Biopharma aims to address unmet medical needs in cancer treatment by combining in-house R&D with strategic global collaborations.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$97.1M
Founded:2018
Ownership:public
Status:operating
FUNDING
Investors:Shanghai Healthcare Capital, Vivo Capital, Shanghai Bio-medical Fund
STOCK
Exchange:HKEX
Ticker:2157
Market Cap:$1.19B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Antibody-drug conjugate (ADC), Monoclonal antibody, Oncolytic virus
Active Trials:58
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Miracogen
Key Partnerships:ArriVent BioPharma (Exclusive license for MRG007 outside Greater China)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Kite Pharma, Advanced Accelerator Applications
LEADERSHIP
Key Executives:
Pu Zhongjie - Chairman
Ziye Sui - CEO
Scientific Founders:Pu Zhongjie
LINKS
Website:lepubiopharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Lepu Biopharma Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Lepu Biopharma Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.